Cocrystal pharma to discuss progress with novel inhaled and oral influenza a antiviral cc-42344 at the world vaccine congress west coast

Bothell, wash., nov. 09, 2023 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”), announces that president and co-ceo sam lee, phd will discuss progress in developing the novel, broad-spectrum pb2 inhibitor cc-42344 in an oral presentation, “taking a new route: development of novel inhaled and oral influenza antiviral, cc-42344” at the world vaccine congress west coast on tuesday, november 28, 2023 at 3:20 p.m. pacific time. the conference is being held november 27-30 at the santa clara convention center in santa clara, calif.
COCP Ratings Summary
COCP Quant Ranking